ArticleDiagnostic pathology2026
Biosensors for oral cancer detection: a scoping review.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This scoping review summarizes recent advances in biosensor technologies for the early, non-invasive detection of oral cancer, with a focus on salivary biomarkers and point-of-care platforms. Five databases (PubMed, Scopus, Web of Science, ProQuest, and EBSCO) were searched for studies published from 2019 to 2025. After duplicate removal and screening, nine eligible original studies were charted. The included platforms were primarily electrochemical, optical, and transistor-based biosensors targeting biomarkers such as interleukin-8 (IL-8), cytokeratin fragment 21.1 (Cyfra 21.1), cancerous inhibitor of PP2A (CIP2A/P90), and high-risk HPV genotypes. Reported limits of detection were frequently in the femtomolar range, although reporting of assay time, sample volume, and clinical diagnostic accuracy was inconsistent. Overall, biosensors show strong analytical potential for oral cancer screening; however, translation to routine clinical use will require standardized analytical validation, careful control of pre-analytical saliva variables, and well-designed multicenter clinical studies reporting sensitivity and specificity against appropriate reference standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.